Monitoring human papillomavirus prevalence in urine samples: A review

Clinical Epidemiology

Volumn 5, Issue 1, 2013, Pages 67-79

  Enerly, Espen ^a   Olofsson, Cecilia ^a   Nygård, Mari ^a  

^a Cancer Registry of Norway ^*  (Norway)

Author keywords

Cervical cancer; Cervix; HPV; Surveillance; Vaccination; Virology

Indexed keywords

GENOMIC DNA; VIRUS DNA;

ADOLESCENT; ADULT; AGE DISTRIBUTION; CHILD; DNA DETERMINATION; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFECTION RISK; MALE; PAPILLOMAVIRUS INFECTION; PREVALENCE; REVIEW; RISK ASSESSMENT; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; URINALYSIS; VIRUS DETECTION;

EID: 84875132882     PISSN: None     EISSN: 11791349     Source Type: Journal    
DOI: 10.2147/CLEP.S39799     Document Type: Review

References (52)

1. Walboomers JM, Jacobs M V, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1): 12-19.
2. Zur Hausen H. Papillomavirus infections - a major cause of human cancers. Biochim Biophys Acta. 1996;1288(2):F55-F78.
3. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classifcation of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518-527.
4. Bosch FX, de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer - burden and assessment of causality. J Natl Cancer Inst Monogr. 2003;31:3-13.
5. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like- particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007;369(9576):1861-1868.
6. Paavonen J, Jenkins D, Bosch FX, et al. Effcacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369(9580):2161-2170.
7. Food and Drug Administration. Center for Biologics and Evaluation and Research, Offce of Vaccines and Related Product Applications. Available from: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094042.htm. Accessed September 17, 2012.
8. Villa LL. HPV prophylactic vaccination: The frst years and what to expect from now. Cancer Lett. 2011;305(2):106-112.
9. Paavonen J, Naud P, Salmeron J, et al. Effcacy of human papillomavi- rus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301-314.
10. Block SL, Brown DR, Chatterjee A, et al. Clinical trial and post- licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine. Pediatr Infect Dis J. 2010;29(2):95-101.
11. Descamps D, Hardt K, Spiessens B, et al. Safety of human papillo- mavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin. 2009;5(5): 332-340.
12. Giuliano AR, Lazcano-Ponce E, Villa L, et al. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis. 2007;196(8):1153-1162.
13. Munoz N, Manalastas R Jr, Pitisuttithum P, et al. Safety, immunogenicity, and effcacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009;373(9679):1949-1957.
14. Romanowski B, de Borba PC, Naud PS, et al. Sustained effcacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04- adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009;374(9706):1975-1985.
15. Ferguson M, Wilkinson DE, Zhou T. WHO meeting on the standard- ization of HPV assays and the role of the WHO HPV Laboratory Network in supporting vaccine introduction held on January 24-25, 2008, Geneva, Switzerland. Vaccine. 2009;27(3):337-347.
16. Monitoring the coverage and impact of human papillomavirus vaccine - report of WHO meeting, Nov 2009. Wkly Epidemiol Rec. 2010;85(25):237-243.
17. Vorsters A, Micalessi I, Bilcke J, Ieven M, Bogers J, Van Damme P. Detection of human papillomavirus DNA in urine. A review of the literature. Eur J Clin Microbiol Infect Dis. 2012;31(5):627-640.
18. Cuschieri K, Nandwani R, McGough P, et al. Urine testing as a surveil- lance tool to monitor the impact of HPV immunization programs. J Med Virol. 2011;83(11):1983-1987.
19. Dunne E F, Nielson CM, Stone KM, Markowitz LE, Giuliano AR. Prevalence of HPV infection among men: A systematic review of the literature. J Infect Dis. 2006;194(8):1044-1057.
20. Giuliano AR, Nielson CM, Flores R, et al. The optimal anatomic sites for sampling heterosexual men for human papillomavirus (HPV) detection: the HPV detection in men study. J Infect Dis. 2007;196(8): 1146-1152.
21. Sehgal A, Gupta S, Parashari A, Sodhani P, Singh V. Urine HPV-DNA detection for cervical cancer screening: prospects and prejudices. J Obstet Gynaecol. 2009;29(7):583-589.
22. Prusty BK, Kumar A, Arora R, Batra S, Das BC. Human papillomavirus (HPV) DNA detection in self-collected urine. Int J Gynaecol Obstet. 2005;90(3):223-227.
23. Manhart LE, Holmes KK, Koutsky LA, et al. Human papillomavirus infection among sexually active young women in the United States: Implications for developing a vaccination strategy. Sex Transm Dis. 2006;33(8):502-508.
24. O'Leary MC, Sinka K, Robertson C, et al. HPV type-specifc prevalence using a urine assay in unvaccinated male and female 11- to 18-year olds in Scotland. Br J Cancer. 2011;104(7):1221-1226.
25. Hussain S, Bharadwaj M, Nasare V, et al. Human papillomavirus infec- tion among young adolescents in India: impact of vaccination. J Med Virol. 2012;84(2):298-305.
26. Alameda F, Bellosillo B, Fuste P, et al. Human papillomavirus detection in urine samples: an alternative screening method. J Low Genit Tract Dis. 2007;11(1):5-7.
27. Bissett SL, Howell-Jones R, Swift C, et al. Human papillomavirus genotype detection and viral load in paired genital and urine samples from both females and males. J Med Virol. 2011;83(10):1744-1751.
28. Daponte A, Pournaras S, Mademtzis I, et al. Evaluation of high-risk human papillomavirus types PCR detection in paired urine and cervical samples of women with abnormal cytology. J Clin Virol. 2006;36(3): 189-193.
29. Forslund O, Hansson BG, Rymark P, Bjerre B. Human papillomavirus DNA in urine samples compared with that in simultaneously collected urethra and cervix samples. J Clin Microbiol. 1993;31(8):1975-1979.
30. Gupta A, Arora R, Gupta S, et al. Human papillomavirus DNA in urine samples of women with or without cervical cancer and their male part- ners compared with simultaneously collected cervical/penile smear or biopsy specimens. J Clin Virol. 2006;37(3):190-194.
31. Jacobson DL, Womack SD, Peralta L, et al. Concordance of human papillomavirus in the cervix and urine among inner city adolescents. Pediatr Infect Dis J. 2000;19(8):722-728.
32. Payan C, Ducancelle A, Aboubaker MH, et al. Human papillomavirus quantifcation in urine and cervical samples by using the Mx4000 and LightCycler general real-time PCR systems. J Clin Microbiol. 2007;45(3):897-901.
33. Rymark P, Forslund O, Hansson BG, Lindholm K. Genital HPV infection not a local but a regional infection: experience from a female teenage group. Genitourin Med. 1993;69(1):18-22.
34. Sellors J W, Lorincz AT, Mahony JB, et al. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervi- cal samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions. CMAJ. 2000;163(5):513-518.
35. Song ES, Lee HJ, Hwang TS. Clinical effcacy of human papillomavirus DNA detection in urine from patients with various cervical lesions. J Korean Med Sci. 2007;22(1):99-104.
36. Stanczuk GA, Kay P, Allan B, et al. Detection of human papillomavirus in urine and cervical swabs from patients with invasive cervical cancer. J Med Virol. 2003;71(1):110-114.
37. Strauss S, Jordens JZ, McBride D, et al. Detection and typing of human papillomavirus DNA in paired urine and cervical scrapes. Eur J Epidemiol. 1999;15(6):537-543.
38. Lazcano-Ponce E, Herrero R, Munoz N, et al. High prevalence of human papillomavirus infection in Mexican males: comparative study of penile-urethral swabs and urine samples. Sex Transm Dis. 2001;28(5): 277-280.
39. Weaver BA, Feng Q, Holmes KK, et al. Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men. J Infect Dis. 2004;189(4):677-685.
40. Hernandez BY, Wilkens LR, Zhu X, et al. Circumcision and human papillomavirus infection in men: a site-specific comparison. J Infect Dis. 2008;197(6):787-794.
41. Arbyn M, Sanjose SD, Saraiya M, et al. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer. 2012;131(9):1969-1982.
42. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-anal- ysis of 1 million women with normal cytological fndings. J Infect Dis. 2010;202(12):1789-1799.
43. de Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7(7): 453-459.
44. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011;29(46):8443-8450.
45. Organization WH. WHO HPV Laboratory Network. Available from: http://www.who.int/biologicals/vaccines/hpv/en/index.html. Accessed November 23, 2012.
46. Johnson AM, Mercer CH, Beddows S, et al. Epidemiology of, and behavioural risk factors for, sexually transmitted human papillomavirus infection in men and women in Britain. Sex Transm Infect. 2012;88(3): 212-217.
47. Wong CA, Saraiya M, Hariri S, et al. Approaches to monitoring biologi- cal outcomes for HPV vaccination: challenges of early adopter countries. Vaccine. 2011;29(5):878-885.
48. Astori G, Pipan C, Muffato G, Botta GA. Detection of HPV-DNA in semen, urine and urethral samples by dot blot and PCR. New Microbiol. 1995;18(2):143-149.
49. Rintala MA, Pollanen P P, Nikkanen V P, Grenman SE, Syrjanen SM. Human papillomavirus DNA is found in the vas deferens. J Infect Dis. 2002;185(11):1664-1667.
50. Fife KH, Coplan PM, Jansen KU, et al. Poor sensitivity of polymerase chain reaction assays of genital skin swabs and urine to detect HPV 6 and 11 DNA in men. Sex Transm Dis. 2003;30(3):246-248.
51. D'Hauwers K, Depuydt C, Bogers J P, et al. Urine versus brushed samples in human papillomavirus screening: study in both genders. Asian J Androl. 2007;9(5):705-710.
52. Shigehara K, Sasagawa T, Kawaguchi S, et al. Prevalence of human papillomavirus infection in the urinary tract of men with urethritis. Int J Urol. 2010;17(6):563-568.